Management of acquired haemophilia A.
J Thromb Haemost. 2011 Jul;9 Suppl 1:226-35
Authors: Collins PW
Summary.? Acquired haemophilia A is an auto-immune disease caused by an inhibitory antibody to factor VIII. The pa…

[Read more →]

How to prevent, treat, and overcome current clinical challenges of VTE.
J Thromb Haemost. 2011 Jul;9 Suppl 1:265-74
Authors: VAN Es J, Eerenberg ES, Kamphuisen PW, Büller HR
Summary.? Venous thromboembolism (VTE) is…

[Read more →]

Management of venous thromboembolism in patients with cancer.
J Thromb Haemost. 2011 Jul;9 Suppl 1:316-24
Authors: Agnelli G, Verso M
Summary.? Patients with cancer are at increased risk of venous thromboembolism (VT…

[Read more →]

Stroke in atrial fibrillation: epidemiology and thromboprophylaxis.
J Thromb Haemost. 2011 Jul;9 Suppl 1:344-51
Authors: Lip GY
Summary.? Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder, w…

[Read more →]

Racial Differences in Venous Thromboembolism.
J Thromb Haemost. 2011 Jul 28;
Authors: Zakai NA, McClure LA
The incidence of venous thrombosis (VTE) varies by race, with African-Americans having over five-fold greater i…

[Read more →]

Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel.
J Thromb Haemost. 2011 Jun 22;
Authors: Fernando H, Bassler N, Habersberger…

[Read more →]

Lupus anticoagulant – performance of the tests as recommended by the latest ISTH guidelines.
J Thromb Haemost. 2011 Jun 25;
Authors: Swadzba J, Iwaniec T, Pulka M, de Laat B, de Groot PG, Musial J
Lupus anticoagulant (…

[Read more →]

Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism. Findings from the RIETE Registry.
J Thromb Haemost. 2011 Jun 15;
Authors: Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todolí JA, Jiménez-Gil…

[Read more →]

Outpatient treatment in patients with acute pulmonary embolism: The Hestia Study.
J Thromb Haemost. 2011 Jun 4;
Authors: Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofste…

[Read more →]

The AVAIL ME extension: a multinational Middle Eastern survey of VTE risk and prophylaxis.
J Thromb Haemost. 2011 May 23;
Authors: Mokhtari M, Salameh P, Kouchek M, Kashani BS, Taher A, Waked M,
Background: Venous th…

[Read more →]

Nonsteroidal anti-inflammatory drug use and risk of venous thromboembolism.
J Thromb Haemost. 2011 May 19;
Authors: Schmidt M, Christiansen CF, Horvath-Puhó E, Glynn RJ, Rothman KJ, Sørensen HT
Background: The associ…

[Read more →]

Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalized patients.
J Thromb Haemost. 2011 Apr 11;
Authors: Lecumberri R, Panizo E, Gomez-Guiu A, Varea S, García-Quetglas E, Serrano M, Ga…

[Read more →]

Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: A systematic review and meta-analysis.

J Thromb Haemost. 2011 Mar 7;

Authors: Carrier M, Rodger M, Wells PS, Righini M, Le Gal G

Background: Residual vein obstruction (RVO) detected on compression ultrasonography of the leg after a few months on anticoagulation therapy might be able to identify patients with deep vein thrombosis (DVT) at high risk of having a recurrent venous thromboembolism (VTE). Purpose: To determine whether RVO is associated with an increased risk of recurrent events in patients with DVT. Data Source: A systematic literature search strategy was conducted using MEDLINE, EMBASE and the Cochrane Register of Controlled Trials. Study Selection: We selected 14 articles (9 prospective cohort studies and 5 randomized controlled trials) that included patients with DVT who had a assessment for RVO using compression ultrasonography. Data extraction: Two reviewers independently extracted data onto standardized forms. Data Synthesis: Overall, the presence of RVO is not associated with an increased risk of recurrent VTE (OR: 1.24, 95% CI: 0.9 to 1.7) in patients with unprovoked DVT that stopped oral anticoagulation therapy at the time of RVO assessment. However, RVO was significantly associated with recurrent VTE in patients with any (unprovoked and provoked) DVT: OR 1.5 (95% CI: 1.1 to 2.0). Conclusion: Residual vein obstruction was associated with a modest increased risk of recurrent VTE in patients with DVT (unprovoked and provoked). However, RVO does not seem to be a predictor of recurrent VTE in patients with unprovoked DVT following anticoagulation discontinuation. Further prospective studies are needed to assess the role of RVO in patients with unprovoked DVT.

PMID: 21382171 [PubMed - as supplied by publisher]

[Read more →]

Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.

J Thromb Haemost. 2011 Feb 16;

Authors: Le Gal G, Carrier M, Kovacs MJ, Betancourt MT, Kahn SR, Wells PS, Anderson DA, Chagnon I, Solymoss S, Crowther M, Righini M, Delluc A, White RH, Vickars L, Rodger M

Objectives:?There is growing interest in using residual vein obstruction (RVO) to guide the duration of oral anticoagulant therapy (OAT) for unprovoked deep vein thrombosis (DVT). We sought to determine if RVO as determined by compression ultrasonography (CUS) after completion of 5 to 7 months of anticoagulation for unprovoked DVT is associated with an increased risk of recurrent venous thromboembolism (VTE). Design:?Multi-centre multi-national prospective cohort study. Setting:?Tertiary care centers. Participants / Methods:?Patients with a first “unprovoked” major VTE were enrolled over a 4 year period and completed mean 18 month follow-up in September 2006. All 452 patients with DVT had baseline CUS at inclusion to assess any RVO before stopping OAT at 5 – 7 months. Main Outcome:?During follow-up off OAT, all episodes of suspected recurrent VTE were independently adjudicated with reference to baseline imaging. Results:?Forty five out of 231 patients with abnormal CUS (19.5%) had recurrent VTE during follow-up, as compared with 32 out of 220 patients with normal CUS (14.6%) and one patient had inadequate CUS. There was no significant association between an abnormal CUS at inclusion and the risk of recurrent VTE: hazard ratio 1.4 (95%CI 0.9 to 2.1), p=0.19. None of the different degrees of clot resolution on baseline CUS was statistically significantly associated with the risk of recurrent VTE. Conclusion:?In our study, the presence of RVO at the time of OAT withdrawal was not associated with a statistically significant higher risk of recurrent VTE. RVO assessment may not be useful to guide duration of anticoagulation.

PMID: 21324057 [PubMed - as supplied by publisher]

[Read more →]

Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage. a meta-analysis of controlled studies.

J Thromb Haemost. 2011 Feb 16;

Authors: Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V

Background and Purpose:?The role of anticoagulants for the prevention of venous thromboembolism in acute hemorrhagic stroke is uncertain. We performed an updated meta-analysis of studies to obtain the best estimates of the efficacy and safety of anticoagulants for the prevention of venous thromboembolism in patients with acute hemorrhagic stroke. Methods:?Using electronic and manual searches of the literature, we identified randomized and non randomized studies comparing anticoagulants (unfractionated heparin or low-molecular-weight heparin or heparinoids) with treatments other than anticoagulants (elastic stockings, intermittent pneumatic compression or placebo) in patients with acute hemorrhagic stroke. Study outcomes included symptomatic and asymptomatic deep venous thrombosis (DVT), symptomatic and asymptomatic pulmonary embolism (PE), any hematoma enlargement or death. Risk Ratio (RR) for individual outcomes were calculated for each study and data from all studies were pooled using the Mantel-Haenszel method. Results:?Four studies (2 randomized) involving 1000 patients with acute hemorrhagic stroke met the criteria for inclusion in this meta-analysis. Compared with other treatments, anticoagulants were associated with a significant reduction in PE (1.7% versus 2.9%, RR 0.37, 95% CI: 0.17 to 0.80, p=0.01), a DVT rate of 4.2% compared to 3.3% (RR 0.77, 95% CI: 0.44 to 1.34, p=0.36), an increase in any hematoma enlargement (8.0% versus 4.0%, RR 1.42; 95% CI: 0.57 to 3.53, p=0.45), and a non significant reduction in mortality (16.1% versus 20.9%, RR 0.76; 95% CI: 0.57 to 1.03, p=0.07). Conclusions:?Our findings indicate that in patients with hemorrhagic stroke, early anticoagulation is associated with a significant reduction in PE, a non significant reduction in mortality, with the trade-off of a non significant increase in hematoma enlargement. These results must be taken with caution and should encourage the assessment of the clinical benefit of antithrombotic prophylaxis in patients with cerebral bleeding by properly designed clinical trials.

PMID: 21324058 [PubMed - as supplied by publisher]

[Read more →]